 | ||||||||
| "weight loss" | ||||||||
| NEWS | ||||||||
CardioBrief: Diet Drug Loses Another Cardiovascular Outcomes Trial In a further sign of the chaos surrounding weight-loss drug naltrexone/bupropion (Contrave), drugmaker Orexigen has again terminated an ...
| ||||||||
| You have received this email because you have subscribed to Google Alerts. |
 Receive this alert as RSS feed |
| Send Feedback |
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.